David gained his PhD from MIT and Harvard Medical School working in diffusion-weighted MRI. He served as Global Head of Imaging at Novartis and then as Head of Research Alliances at GE Healthcare, before founding Lightpoint Medical to develop a novel miniaturised gamma ray sensor for surgery for prostate cancer and other conditions. After building the company over 10 years, he recently exited Lightpoint Medical to Telix Pharmaceuticals.

David has supported Lucida Medical since 2021.

• 

  Chair of the Board in Lucida

  Medical device software using AI to find cancer precisely and fast with MRI, focusing on prostate cancer | Hiring now